Informationen:
Fehler:
ID
13210
Beschreibung
Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally; ODM derived from: https://clinicaltrials.gov/show/NCT00083538
Link
https://clinicaltrials.gov/show/NCT00083538
Stichworte
Versionen (1)
- 24.01.16 24.01.16 -
Hochgeladen am
24. Januar 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Multiple Myeloma NCT00083538
Eligibility Multiple Myeloma NCT00083538
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Multiple Myeloma NCT00083538
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
multiple myeloma
Item
patients must have confirmed diagnosis of one of the following: smoldering or indolent multiple myeloma, multiple myeloma more than 1 year after autologous transplant and with stable disease, or multiple myeloma with cytogenetic abnormalities
boolean
C0026764 (UMLS CUI [1])
secretion
Item
patients with secretory iga or igg must have purified idiotype protein available and/or tumor cells available, and patients with light chain or non-secretory myeloma must have tumor cells available
boolean
C0036536 (UMLS CUI [1])
karnofsky
Item
karnofsky performance score greater than or equal to 60
boolean
C0206065 (UMLS CUI [1])
anc, platelet count, cd4 count
Item
anc greater than or equal to 1,000/microliters, platelet count greater than or equal to 60,000/microliters, and cd4 count greater than or equal to 400/microliters.
boolean
C0948762 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
C0243009 (UMLS CUI [3])
C0032181 (UMLS CUI [2])
C0243009 (UMLS CUI [3])
life expectancy
Item
expected survival of 3 months or more
boolean
C0023671 (UMLS CUI [1])
age
Item
18 years of age and older
boolean
C0001779 (UMLS CUI [1])
informed consent
Item
have given a written consent and been informed about the investigational nature of the study.
boolean
C0021430 (UMLS CUI [1])
hiv, hepatitis b, hepatitis c
Item
negative serology for hiv, hepatitis c, and negative for hepatitis b surface antigen
boolean
C0019682 (UMLS CUI [1])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])
cd4 count, immune system dysfunction
Item
patients with cd4 count < 400/microliters, and/or with severely damaged immune functions
boolean
C2698595 (UMLS CUI [1])
C0020962 (UMLS CUI [2,1])
C0277785 (UMLS CUI [2,2])
C0020962 (UMLS CUI [2,1])
C0277785 (UMLS CUI [2,2])
chemotherapy, immunosuppression
Item
chemotherapy or other immunosuppressive treatment with steroids, cytoxan, methotrexate within 8 weeks
boolean
C0392920 (UMLS CUI [1])
C0021079 (UMLS CUI [2])
C0021079 (UMLS CUI [2])
infection, fever
Item
fever or active infection
boolean
C0009450 (UMLS CUI [1])
C0015967 (UMLS CUI [2])
C0015967 (UMLS CUI [2])
bilirubin, ast, alt
Item
liver function: total bilirubin greater than or equal to 2 x uln or ast/alt greater than or equal to 3 x uln
boolean
C1278039 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0201836 (UMLS CUI [3])
C0201899 (UMLS CUI [2])
C0201836 (UMLS CUI [3])
dialysis
Item
renal function: patients on dialysis
boolean
C0011946 (UMLS CUI [1])
medication
Item
simultaneous treatment with a second investigational drug or biologic agent
boolean
C0013227 (UMLS CUI [1])
C2348568 (UMLS CUI [2])
C2348568 (UMLS CUI [2])